VI
CERE

Versor Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Versor Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-44,194
Closed -$1.81M – 1033
2024
Q2 		$1.81M Sell
44,194
-85,323
-66% -$3.55M 0.33% 50
2024
Q1 		$5.47M Buy
129,517
+20,860
+19% +$876K 1.11% 8
2023
Q4 		$4.61M Buy
+108,657
New +$3.12M 0.94% 9

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Versor Investments's CERE Position: Q3 2024 in Review

Versor Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 44,194 shares — an estimated $1.81M sold.

Versor Investments first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $5.47M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Versor Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Versor Investments sold 44,194 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.81M.
  • Versor Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Versor Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.47M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Versor Investments's 13F filing for Q3 2024, filed 4 Nov 2024.